Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
Provided By GlobeNewswire
Last update: Nov 4, 2025
Bolsters balance sheet with non-dilutive capital at an attractive cost
Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price
Read more at globenewswire.com
